Send Message
View as an RSS Feed
  • Ocata Therapeutics Science For The Lay Person  [View article]
    rd88, do not be so optimistic. Astellas will continue the research with same people in the US and additional Japanese scientists. They will get Japanese patients into the trial but skip the separate control group and prolonged unneeded immunosuppression trials.They will then get Jap FDA to approve it and start treatment in Japan.

    Astellas will not be free to use the treatment in the US until US FDA approval. That will take many years. In the meantime they will treat their own people but not foreigners because they will have more than they can handle. So this selling to the Japanese is screwing the American people who are or have gone blind. Paul Wotton is British --- send him back to England!
    Jan 22, 2016. 06:25 PM | 2 Likes Like |Link to Comment
  • Sorting Out Ocata Management's Words And Deeds  [View article]
    Fellow long term share holders, hang on to your shares and let us deprive Astellas and Wotton and BOD of getting the 50+% tender they need to close the deal. OCATA is worth at least $25 if they carry their Trials to commercialization.
    Jan 12, 2016. 09:07 PM | 2 Likes Like |Link to Comment
  • Healios and Athersys Enter Into Regenerative Medicine Partnership for Treatment of Stroke Using MultiStem┬« Therapy  [View article]
    This is a great vote of confidence in the treatment of stroke patients using ATHX's Multistem. ATHX should be getting FDA approval shortly to proceed with further trials on IS with a revised treatment time after an IS of between 16 to 36 hours instead of the earlier trial range of 24 to 48 hours.

    This is a big deal. This puts needed money into ATHX coffers that will avoid them having to raise money in the market, selling shares and the resulting dilution.
    Jan 8, 2016. 10:05 AM | Likes Like |Link to Comment
  • Ocata Management Pulls Out All Stops To Push Astellas Merger Forward  [View article]
    Ex CEO Rabin (ousted last March?) is looking better and better. He truly cared for ACTC. Unfortunately he got booted because he needed money and he did not want ACTC shares to go down, he hid his sale..... and got caught. I do not know if he is barred by the SEC from working in the industry again. If not him, OCAT should fire PW for cause and find one like Rabin who truly cared for his company...... maybe a long time employee who cares for the company's future.... or even a dissenter from the existing Board.
    Jan 7, 2016. 10:28 AM | 3 Likes Like |Link to Comment
  • Sirius XM: Disappointing Guidance May Annoy, But Expecting Otherwise Is Just Plain Silly  [View article]
    Tigerjohnni, selloff and price decline is because the guidance is low. Price of stocks go up because buyers are expecting a bight future, like when Apple announces something big coming, a revolutionary product for example. SIRI has not done anything like that. And they have not even bothered to pique investors interest by announcing features of SXM 17. The private showing indicates to me that SIRI is testing the waters to see how the OEMS will react. The product is not ready for release now, maybe later this year, depending on OEM comments.
    Jan 7, 2016. 09:13 AM | 1 Like Like |Link to Comment
  • Premarket Biotech Digest: My Response, Gilead In 2016, Blow For Vivus  [View article]
    He was defending himself so the many "I"s. Did you expect him to use a lot you "you's", "us's" and "we's"?
    Jan 1, 2016. 10:48 AM | 9 Likes Like |Link to Comment
  • Astellas Whiffs At First Bid For Ocata, Can Wotton Survive?  [View article]
    Thanks for writing this article. I was distressed with the tender offer made at such a low price for a company that is so close to confirming (already proved it) that its science works and will be helping millions of people regain their eyesight.

    Paul Wotton has no history of managing a company that went from research to a successful commercialization, to exploiting all its assets. His attempt at selling OCATA a year and a half after he took over shows he has no intention of staying long. He just wants to make himself rich and then go elsewhere. He clearly should not be running OCATA, a company that has a great future what with all the science it has developed.
    Dec 22, 2015. 09:42 AM | 14 Likes Like |Link to Comment
  • Sirius XM CFO Discusses 2016 Debt Plans  [View article]
    I learned my lesson looking at $4.18 in 2013 and doing nothing, then watching it go down and down. This time I sold some of my holdings at $4.20 and invested elsewhere. I am still holding a good number of SIRI shares.
    Dec 21, 2015. 01:25 AM | Likes Like |Link to Comment
  • Saudi Arabia forms coalition against terror  [View news story]
    Trump was immediately vilified by Critics and most of his own Republican Party and continue to be mocked after he banned non US citizen Muslims from entering the US. After this move by the Saudis - meant to go after their terrorists, it looks like Trump's proposal to ban Muslims is having a positive effect against terrorism.
    Dec 15, 2015. 09:45 AM | Likes Like |Link to Comment
  • Sirius XM Holdings: The ~99% Debt Financed Capital Structure Is Concerning  [View article]
    SIRI keeps its debt below 4%. Its cash flow can easily payoff this debt which is very low interest. After this year, that is what they will start to do. They pay it off in preparation for the end of their NOL reserves and the need to send up a couple of new satellites.

    One asset that is hard to put a value on is their satellite spectrum. After they switch most of the customers to one system --XM, spectrum will be freed up for their own use or for lease. I do not think they will ever sell this asset for a one time gain.
    Dec 14, 2015. 04:28 PM | 6 Likes Like |Link to Comment
  • Data for Neuralstem's Novel NSI-189 Molecule in Major Depressive Disorder Published in Molecular Psychiatry  [View article]
    This is very encouraging! Looks like it benefits a very high percentage of patients.
    Dec 9, 2015. 09:52 AM | Likes Like |Link to Comment
  • InVivo Therapeutics cleared to convert INSPIRE study to show probable benefit; shares up 8% premarket  [View news story]
    The pivotal trial conversion will involve 20 patients. If my previous understanding is correct, the NVIV will get credit for the first 5 already done so they will really have to do only 15 more. With T2 addition, this will make it easier to get 15 more patients compared to the first 5 which took about 10 months. If I am correct, perhaps by the 1st quarter, they could complete all 15 in 4 months.
    Dec 3, 2015. 09:56 AM | 1 Like Like |Link to Comment
  • Sirius XM Holdings (SIRI) Presents at Bank of America Merrill Lynch 2015 Leveraged Finance Brokers Conference (Transcript)  [View article]
    Come on guys. You comment like you have never read or heard rambling English, English that have no use for periods or commas and multi pharagraph long sentences.
    Dec 2, 2015. 09:00 PM | 2 Likes Like |Link to Comment
  • BioTime Could Be The Next Acquisition Target In The Stem Cell Sector  [View article]
    Wooton mentioned one reason but did not fully explain. Here is my take.

    FDA allows only patients who are really healthy so that when they give them an immuneno suppression drug, they will not get sick and be hurt. People who have AMD and SMD are mostly elderly and are not in the best of health. This makes it harder to qualify patients for the trial. OCAT therefore want the FDA to loosen the criteria a little bit.
    Dec 2, 2015. 10:00 AM | Likes Like |Link to Comment
  • MagicJack VocalTec: The Disappearing Business Trick  [View article]
    I use magic Jack apps when I am traveling abroad... calling any number in the US and friends around the world who have MJ. It has been worth many times over the 20/year fee.
    Nov 25, 2015. 12:43 PM | 1 Like Like |Link to Comment